• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CervoMed Inc.

    11/14/24 3:09:10 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVO alert in real time by email
    SC 13G 1 cervomed13g093024t.txt CRVO 13G THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CervoMed, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 15713L109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person?s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 15713L109 (1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (entities only): AWM Investment Company, Inc. (2) Check the Appropriate Box if a Member of a Group (See Instructions) (a)___ b)___ (3) SEC Use Only (4) Citizenship or Place of Organization: Delaware, United States Number of Shares Beneficially Owned by Each Reporting Person With (5) Sole Voting Power: 854,171** (6) Shared Voting Power: 0** (7) Sole Dispositive Power: 854,171** (8) Shared Dispositive Power: 0** (9) Aggregate Amount Beneficially Owned by Each Reporting Person: 854,171** (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): (11) Percent of Class Represented by Amount in Row (9): 9.9%** (12) Type of Reporting Person (See Instructions): IA **AWM Investment Company, Inc., a Delaware Corporation (AWM), is the investment adviser to Special Situations Cayman Fund, L.P. (CAYMAN), Special Situations Fund III QP, L.P. (SSFQP) and Special Situations Life Sciences Fund, L.P. (SSLS). (CAYMAN, SSFQP, and SSLS will hereafter be referred to as the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 277,234 shares of Common Stock of the Issuer (the Shares) and 235,126 Warrants*** to purchase Shares of Common Stock held by SSFQP, 77,729 shares of Common Stock and 68,748 Warrants*** to purchase Shares of Common Stock held by CAYMAN and 94,043 shares of Common Stock and 101,291 Warrants*** to purchase Shares of Common Stock held by SSLS. See Items 2 and 4 of this Schedule for additional information. *** The Warrants described herein may only be exercised to the extent that the total number of Common Shares then beneficially owned does not exceed 9.99% of the outstanding shares. Item 1(a). Name Of Issuer: CervoMed, Inc. Item 1(b). Address of Issuer?s Principal Executive Offices: 20 Park Plaza ? Suite 424 Boston, Massachusetts 02116 Item 2(a). Name of Person Filing: The person filing this report is AWM Investment Company, Inc., a Delaware corporation (AWM), which is the investment adviser to Special Situations Cayman Fund, L.P., a Cayman Islands Limited Partnership (CAYMAN), Special Situations Fund III QP, L.P., a Delaware limited partnership (SSFQP) and Special Situations Life Sciences Fund, L.P., a Delaware limited partnership (SSLS), (CAYMAN, SSFQP, SSPE and SSLS, will hereafter be referred to as the Funds). The principal business of each Fund is to invest in equity and equity-related securities and other securities of any kind or nature. David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are members of: SSCayman, L.L.C., a Delaware limited liability company (SSCAY), the general partner of CAYMAN; MGP Advisers Limited Partnership, a Delaware limited partnership (MGP), the general partner of SSFQP and LS Advisers, L.L.C., a New York limited liability company (LS). Greenhouse and Stettner are also controlling principals of AWM. Item 2(b). Address of Principal Business Office or, if None, Residence: The principal business address for AWM is c/o Special Situations Funds, 527 Madison Avenue, Suite 2600, New York, NY 10022. Item 2(c). Citizenship: AWM is a Delaware Corporation. Item 2(d). Title of Class of Securities: Common Stock, $0.001 Par Value Item 2(e). CUSIP No.: 15713L109 Item 3. If This Statement Is Filed Pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a: Not Applicable. Item 4. Ownership (a) Amount Beneficially Owned: 854,171** (b) Percent of Class: 9.9%** (c) Number of Shares as to which the person has: (i) sole power to vote or to direct the vote: 854,171** (ii) shared power to vote or to direct the vote: 0** (iii) sole power to dispose or to direct the disposition of: 854,171** (iv) shared power to dispose or to direct the disposition of: 0** ______________________________________________________________________ ** AWM is the investment adviser to each of the Funds. As the investment adviser to the Funds, AWM holds sole voting and investment power over 277,234 shares of Common Stock of the Issuer (the Shares) and 235,126 Warrants*** to purchase Shares of Common Stock held by SSFQP, 77,729 shares of Common Stock and 68,748 Warrants*** to purchase Shares of Common Stock held by CAYMAN and 94,043 shares of Common Stock and 101,291 Warrants*** to purchase Shares of Common Stock held by SSLS. Greenhouse and Stettner are members of: SSCAY, the general partner of CAYMAN; MGP, the general partner of SSFQP; MG, the general partner of SSPE; and LS, the general partner of SSLS. Greenhouse and Stettner are also controlling principals of AWM. Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ___ Item 6. Ownership of More Than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person Not Applicable. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 14, 2024 AWM INVESTMENT COMPANY, INC. By:/s/ Adam Stettner Name: Adam Stettner Title: Executive Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) -1-
    Get the next $CRVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRVO

    DatePrice TargetRatingAnalyst
    3/13/2025$14.00Neutral → Buy
    Chardan Capital Markets
    12/17/2024Buy → Neutral
    H.C. Wainwright
    12/11/2024Buy → Neutral
    Chardan Capital Markets
    12/11/2024Overweight → Underweight
    Morgan Stanley
    12/10/2024Buy → Hold
    D. Boral Capital
    12/6/2024$45.00Buy
    ROTH MKM
    12/5/2024$42.00Buy
    H.C. Wainwright
    9/18/2024$55.00Buy
    Chardan Capital Markets
    More analyst ratings

    $CRVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CervoMed Inc.

      SC 13G - CervoMed Inc. (0001053691) (Subject)

      11/14/24 3:09:10 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CervoMed Inc.

      SC 13G - CervoMed Inc. (0001053691) (Subject)

      4/11/24 7:55:23 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CervoMed Inc. (Amendment)

      SC 13G/A - CervoMed Inc. (0001053691) (Subject)

      3/6/24 4:05:55 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    SEC Filings

    See more
    • SEC Form 424B5 filed by CervoMed Inc.

      424B5 - CervoMed Inc. (0001053691) (Filer)

      5/12/25 5:13:43 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CervoMed Inc. (0001053691) (Filer)

      5/12/25 4:29:50 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by CervoMed Inc.

      10-Q - CervoMed Inc. (0001053691) (Filer)

      5/12/25 9:06:44 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities Initiating separate Phase 2a trials to evaluate neflamapimod in patients with primary progressive aphasia and patients in the recovery phase after ischemic stroke BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported its financia

      5/12/25 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

      BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held in New York, NY, on Tuesday, May 20, 2025. Presentation DetailsFormat: Fireside ChatDate: Tuesday, May 20, 2025Time: 5:00 – 5:30 PM ETWebcast Link: https://journey.ct.events/view/ff005743-cd3c-4c4c-bd4d-ba8d0c84c859 The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website htt

      5/7/25 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

      During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC) Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at AD/PD™ 2025 demonstrates improvements on endpoints measuring cognitive fluctuations and working memory The results demonstrate proof-of-concept for neflamapimod as a treatment for dementia with Lewy bodies (DLB) BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage comp

      4/2/25 7:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CervoMed upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded CervoMed from Neutral to Buy and set a new price target of $14.00

      3/13/25 7:28:49 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed downgraded by H.C. Wainwright

      H.C. Wainwright downgraded CervoMed from Buy to Neutral

      12/17/24 7:40:50 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded CervoMed from Buy to Neutral

      12/11/24 7:28:58 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO & GC Elder William Robert bought $18,160 worth of shares (1,000 units at $18.16), increasing direct ownership by 375% to 1,267 units (SEC Form 4)

      4 - CervoMed Inc. (0001053691) (Issuer)

      8/27/24 4:09:50 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Financials

    Live finance-specific insights

    See more
    • CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

      A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Improvement (p=0.035 against either old capsules or placebo) also demonstrated on the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (CGIC) Compared to either old capsules or placebo, a lower incidence of falls was seen in participants receiving study drug from the new batch of capsules during the extension phase Company to host investor webcast at 5:00 PM ET today to discuss results BOSTON, March 10,

      3/10/25 4:05:00 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Leadership Updates

    Live Leadership Updates

    See more
    • CervoMed to Appoint William Elder as Chief Financial Officer

      BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition. "Bill's deep biopharmaceutical and financial expertise and strong track record of enhancing operational capabilities makes him

      5/20/24 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

      - Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025 - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024 - Integrated summary of results from AscenD-LB Phase 2a trial published in peer-reviewed journal and presentations at a major scientific conference further inform on the potential of neflamapimod in DLB and proba

      4/1/24 8:00:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

      Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical comp

      2/7/24 8:30:00 AM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gregoire Sylvie

      4 - CervoMed Inc. (0001053691) (Issuer)

      2/14/25 6:02:31 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO & GC Elder William Robert

      4 - CervoMed Inc. (0001053691) (Issuer)

      2/14/25 6:02:02 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Cobuzzi Robert Joseph Jr.

      4 - CervoMed Inc. (0001053691) (Issuer)

      2/14/25 6:01:32 PM ET
      $CRVO
      Biotechnology: Pharmaceutical Preparations
      Health Care